Redesigns development and manufacturing approach to support increasingly complex and fast-moving market needs. Read More >>
Strengthens its ability to provide a seamless path from DNA to IND submission for its customers.
Our enhanced offering enables mAb programs to achieve IND readiness in as little as 6 months, with tox‑grade DS available in ~2 months.
The two companies have collaborated on other fronts since 2021.
New compact platform combines gel running and imaging for faster nucleic acid verification.
How to compare CMO proposals and know what your true costs will be.
The Chai-3 model aims to help accelerate drug discovery research.
With expertise in traditional and advanced therapies, Cardinal Health Regulatory Sciences will collaborate throughout the product lifecycle to help achieve your regulatory goals. Learn more.
